Last reviewed · How we verify

NCT03485781: PROPEA3

Propofol-induced EEG Changes in Hypoxic Brain Injury

Completed Last updated 25 March 2020
What this trial tests

trial in Hypoxic-Ischemic Encephalopathy in 102 participants. Completed in 10 July 2019.

Timeline
12 October 2017
Primary endpoint
10 July 2019
10 July 2019

Quick facts

Lead sponsorUniversity of Oulu
StatusCompleted
Study typeOBSERVATIONAL
Enrollment102
Start date12 October 2017
Primary completion10 July 2019
Estimated completion10 July 2019
Sites2 locations across Finland

Conditions studied

Sponsor

University of Oulu

Who can join

18 and older, any sex, with Hypoxic-Ischemic Encephalopathy or Cardiac Arrest. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PROPEA3 is a prospective observational study investigating the recovery of propofol-induced EEG slow-wave activity and its association with neurological outcome after cardiac arrest.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. ESICM LIVES 2019 : Berlin, Germany. 28 September - 2 October 2019.
    · 2019 · cited 8× · PMID 31559498 · DOI 10.1186/s40635-019-0265-y

Verify or expand the search:

Other recruiting trials for Hypoxic-Ischemic Encephalopathy

Currently open trials in the same condition.

Other University of Oulu trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03485781.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing